Beckley Psytech Commences Phase 2a Trial for

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
180
Beckley Psytech Commences Phase 2a Trial for Treatment-Resistant Depression

Beckley Psytech is a clinical-stage biotechnology company focused on improving the lives of individuals living with neuropsychiatric disorders through the development of psychedelic drugs. In its latest press release, the company revealed that it has administered a new intranasal psychedelic using an FDA-approved delivery device to a patient with treatment-resistant depression during a phase 2a trial.

The objective of the phase 2 trial is to assess the effectiveness, safety and pharmacokinetics of the company’s BPL-003 formulation when administered together with psychological support, to patients experiencing moderate to severe symptoms of treatment-resistant depression. BPL-003 is a synthetic formulation of the 5-MeO-DMT compound.

It is estimated that roughly 3.8% of the global population suffers from depression, which adds up to about 280 million individuals. Treatment-resistant depression (refractory depression) is used to describe individuals suffering from major depressive disorder who don’t respond to antidepressant medications.

In its press release, the company revealed that BPL-003 had been well tolerated during the phase 1 trial. The researchers determined that high as well as medium dosages could induce profound psychedelic experiences with a timely offset of treatment effects.

During the trial, patients will receive a single dose of the psychedelic formulation then be followed for a three-month period, with effectiveness and safety evaluations being conducted throughout the period.

Rob Conley, the company’s chief scientific officer, stated that it had been exciting to dose the study’s first patient, adding that the company looked forward to investigating the possible therapeutic effects of the drug for treatment-resistant depression patients. He further noted that about one-third of all patients living with depression were resistant to standard treatments and there was need for more effective therapies. Conley then added that Beckley Psytech was proud to be pioneering a new way to develop alternative treatments that were effective, safe and practical.

The company expects to have results from the trial by the end of this year. The findings, together with data from a phase 2b trial to be held next year, will be used to inform development of the BPL-003 formulation in the future.

Beckley Psytech received the approval for its Investigational New Drug application from the FDA earlier this year. Phase 2b of this trial will be focused on evaluating the effects of one medium or high dose of its psychedelic formulation against microdoses. This study will occur across seven different countries, at 40 research sites. Meanwhile, the phase 2a trial is currently recruiting at Hammersmith Medicines Research and King’s College London.

This particular clinical trial is just one of the many ongoing or planned psychedelic studies that numerous entities such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are financing in order to explore how best these substances can be harnessed for human health.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer


Delic Holdings Corp (DELCF) Stock Research Links

DELCF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 23

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 63

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading